NFKB1 and colorectal cancer: KRAS mutation in colorectal cancer drives immune evasion by sensitizing cytotoxic T‐cells to activation‐induced cell death through lactic acid‐mediated NF‐κB inactivation, and thus impairs immunotherapeutic efficacy.